Study of Interstitial Lung Diseases Linked to Rheumatic and Connective Tissue Diseases in Mexico Tracking Disease Progression and Risk Factors

What this Trial Is About

Researchers are studying the epidemiology of interstitial lung diseases ILD linked to connective tissue diseases CTD in Mexico. They aim to understand how different comorbidities and treatments affect disease progression, flare-ups, and mortality in these patients. This observational study covers various rheumatic diseases such as rheumatoid arthritis, systemic sclerosis, inflammatory myopathies, systemic lupus erythematosus, and others, focusing on their association with ILD. All participants must have diagnoses of both a connective tissue disease and interstitial lung disease confirmed by clinical evaluation and high-resolution computed tomography. The study collects data from medical records spanning the past ten years 2012 to 2022 and from new patient consultations over the next three years 2023 to 2026. Participant observation time varies depending on whether data is historical, ongoing, or both. Participants medical records and clinical information will be reviewed, including lung imaging, lung function tests, and patient questionnaires assessing respiratory health and quality of life. Researchers will track the time to first exacerbation, frequency of flare-ups, extent of lung fibrosis, and changes in walking tests and respiratory questionnaires over up to 13 years. The study will also monitor factors influencing disease progression and treatment patterns. Participation duration varies based on data availability and collection period.

Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) Epidemiology Non-interventional Study (NIS)